Volume | 50,121 |
|
|||||
News | - | ||||||
Day High | 1.409 | Low High |
|||||
Day Low | 1.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Petros Pharmaceuticals Inc | PTPI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.30 | 1.30 | 1.409 | 1.34 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
182 | 50,121 | $ 1.36 | $ 67,955 | - | 0.9172 - 9.54 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:11:05 | 100 | $ 1.335 | USD |
Petros Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.93M | 2.20M | - | 9.38M | -20.04M | -9.10 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Petros Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTPI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.36 | 2.00 | 1.25 | 1.48 | 533,485 | -0.025 | -1.84% |
1 Month | 1.39 | 2.00 | 1.20 | 1.47 | 146,877 | -0.055 | -3.96% |
3 Months | 1.96 | 2.13 | 1.20 | 1.55 | 78,435 | -0.625 | -31.89% |
6 Months | 2.38 | 4.74 | 1.20 | 3.33 | 216,091 | -1.05 | -43.91% |
1 Year | 3.15 | 9.54 | 0.9172 | 4.73 | 764,039 | -1.82 | -57.62% |
3 Years | 33.00 | 59.599 | 0.9172 | 26.54 | 2,072,597 | -31.67 | -95.95% |
5 Years | 18.00 | 59.599 | 0.9172 | 26.54 | 2,064,647 | -16.67 | -92.58% |
Petros Pharmaceuticals Description
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease. |